Charles River Laboratories (CRL)

• Market cap: $5.83B
• 1 day: 1.13%
• 5 days: 7.43%
• 1 month: -21.19%
• 3 months: -28.36%
• 6 months: -34.60%
• Year to date: -35.05%
• 1 year: -48.20%
• 5 years: -18.01%
• 10 years: 71.52%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 20,100

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

18% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 83

2.66% more ownership

Funds ownership: 100.13% [Q3] → 102.79% (+2.66%) [Q4]

1% more funds holding

Funds holding: 619 [Q3] → 624 (+5) [Q4]

1% less capital invested

Capital invested by funds: $10.2B [Q3] → $10B (-$149M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

36% less repeat investments, than reductions

Existing positions increased: 175 | Existing positions reduced: 275

42% less call options, than puts

Call options by funds: $28.5M | Put options by funds: $49.3M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $145 22% upside
• Avg. target: $167 41% upside
• High target: $184 55% upside

7 analyst ratings

• positive: 0 0%
• neutral: 7 100%
• negative: 0 0%

Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target	22% upside $145	Equal-Weight Maintained	10 Apr 2025
Mizuho Ann Hynes 57% 1-year accuracy 12 / 21 met price target	31% upside $155	Neutral Maintained	9 Apr 2025
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target	43% upside $170	Neutral Downgraded	21 Mar 2025
Citigroup Patrick Donnelly 27% 1-year accuracy 8 / 30 met price target	48% upside $175	Neutral Upgraded	4 Mar 2025
JP Morgan Casey Woodring 0% 1-year accuracy 0 / 7 met price target	39% upside $165	Neutral Maintained	20 Feb 2025